World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
34261
World Ranking
12556
National Ranking
6426

Mark C. Gebhardt publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark C. Gebhardt sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 309 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark C. Gebhardt D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark C. Gebhardt sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark C. Gebhardt is affiliated with Harvard Medical School in the United States and has contributed extensively to the field of medicine, with a particular focus on surgery. Their research encompasses a broad range of subfields including pulmonary and respiratory medicine, public health, environmental and occupational health, cardiology and cardiovascular medicine, and rheumatology.

The primary topics of Gebhardt's work include sarcoma diagnosis and treatment, cardiac, anesthesia and surgical outcomes, bone tumor diagnosis and treatments, diversity and career in medicine, meta-analysis and systematic reviews, management of metastatic bone disease, and anesthesia and pain management.

Gebhardt has published numerous papers in prominent venues. Frequent publication venues include:

  • Clinical Orthopaedics and Related Research
  • UNC Libraries
  • Cancer
  • Journal of Pediatric Orthopaedics
  • JBJS Open Access

Recent papers authored or coauthored by Gebhardt cover a diverse range of topics and years of publication. Notable works include:

  • Editorial: What CORR ® Seeks From Papers About New Implants and Techniques, 2022, Clinical Orthopaedics and Related Research
  • Complete tumor necrosis after neoadjuvant chemotherapy defines good responders in patients with Ewing sarcoma, 2022, Cancer
  • Editorial: Opposites Attract at CORR®-Machine Learning and Qualitative Research, 2020, Clinical Orthopaedics and Related Research
  • What Are Risk Factors for and Outcomes of Late Amputation After Treatment for Lower Extremity Sarcoma: A Childhood Cancer Survivor Study Report, 2022, Clinical Orthopaedics and Related Research
  • Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Chest Wall: Impact of Initial Versus Delayed Resection on Tumor Margins, Survival, and Use of Radiation Therapy, 2021, UNC Libraries

Collaborations represent an important component of Gebhardt's research activity. Frequent coauthors include Seth S. Leopold, Terence J. Gioe, Paul Manner, Raphaël Porcher, and Clare M. Rimnac, each having collaborated on multiple publications.

Best Publications

  • A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system.

    William F. Enneking;William Dunham;Mark C. Gebhardt;Martin Malawar

  • Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

    Holcombe E Grier;Mark D Krailo;Nancy J Tarbell;Michael P Link

  • p53 functions as a cell cycle control protein in osteosarcomas.

    L Diller;J Kassel;C E Nelson;M A Gryka

  • Long-term results of allograft replacement in the management of bone tumors.

    Henry Mankin;Mark Gebhardt;L. Jennings;Dempsey Springfield

  • Biology and Therapeutic Advances for Pediatric Osteosarcoma

    Neyssa Marina;Mark Gebhardt;Lisa Teot;Richard Gorlick

  • Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

    Paul A. Meyers;Cindy L. Schwartz;Mark D. Krailo;John H. Healey

  • Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate

    Paul A. Meyers;Cindy L. Schwartz;Mark Krailo;Eugenie S. Kleinerman

  • Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment.

    Daniel Rosenthal;Francis Hornicek;Michael Wolfe;L. Jennings

  • Infection in bone allografts. Incidence, nature, and treatment.

    C F Lord;M C Gebhardt;W W Tomford;H J Mankin

  • Osteoid osteoma: percutaneous treatment with radiofrequency energy.

    Daniel I Rosenthal;Francis J Hornicek;Martin Torriani;Mark C Gebhardt

  • Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Neyssa M Marina;Sigbjørn Smeland;Stefan S Bielack;Mark Bernstein

  • Chondrosarcoma of Bone: An Assessment of Outcome*

    Francis Y. Lee;Henry J. Mankin;Gertrude Fondren;Mark C. Gebhardt

  • Recurrence of giant-cell tumors of the long bones after curettage and packing with cement.

    Richard O'Donnell;Dempsey Springfield;Haresh Motwani;John Ready

  • Aneurysmal Bone Cyst: A Review of 150 Patients

    Henry J. Mankin;Francis J. Hornicek;Eduardo Ortiz-Cruz;Jorge Villafuerte

  • Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Sigbjørn Smeland;Stefan S. Bielack;Jeremy Whelan;Mark Bernstein

  • Fractures of allografts. Frequency, treatment, and end-results.

    B H Berrey;C F Lord;M C Gebhardt;H J Mankin

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina

  • USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts.

    Andre M. Oliveira;Andre M. Oliveira;Antonio R. Perez-Atayde;Carrie Y. Inwards;Fabiola Medeiros

  • Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651

    Allen M. Goorin;Douglas J. Schwartzentruber;Meenakshi Devidas;Mark C. Gebhardt

  • Osteoid osteoma: Percutaneous radio-frequency ablation

    Daniel I. Rosenthal;Dempsey S. Springfield;Mark C. Gebhardt;Andrew E. Rosenberg

Frequent Co-Authors

Henry J. Mankin
Henry J. Mankin Harvard University
Francis J. Hornicek
Francis J. Hornicek University of Miami
Holcombe E. Grier
Holcombe E. Grier Harvard University
Andrew E. Rosenberg
Andrew E. Rosenberg University of Miami
Antonio R. Perez-Atayde
Antonio R. Perez-Atayde Boston Children's Hospital
Mark Krailo
Mark Krailo University of Southern California
Daniel I. Rosenthal
Daniel I. Rosenthal Harvard University
Herman D. Suit
Herman D. Suit Harvard University
Paul A. Meyers
Paul A. Meyers Memorial Sloan Kettering Cancer Center
Nancy J. Tarbell
Nancy J. Tarbell Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine, a growing number of online degree options offer flexible and accelerated routes to a healthcare career. Programs like the shortest online dnp program allow qualified nurses to quickly advance their education and job prospects. Additionally, candidates with busy schedules or who seek alternatives to in-person experiences can opt for online dnp programs without clinicals, eliminating the need for traditional on-site placements.

Those beginning their healthcare journey may consider an accelerated lpn program, which provides a rapid pathway into nursing practice, often in under a year. For those looking to specialize, advanced programs such as online psych np programs enable registered nurses to become Psychiatric Mental Health Nurse Practitioners (PMHNP), a field with growing demand in the US.

These diverse online pathways offer flexibility and accessibility, helping students shape their medical careers to suit personal goals and evolving industry needs.

Best Scientists Citing Mark C. Gebhardt

Trending Scientists

Recently Published Articles